MedPath

Pilot Study Comparing 10hz vs Theta Burst Stimulation

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Device: iTBS
Device: 10Hz
Registration Number
NCT02800226
Lead Sponsor
University of British Columbia
Brief Summary

This pilot study aims at exploring the efficacy of iTBS compared to 10Hz protocol and explore potential biomarkers of treatment response

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • outpatients
  • voluntary and competent to consent
  • Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of Major Depressive Disorder (MDD), single, recurrent between ages 18-65
  • failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of ≥ 3 in the current episode or have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF 1 or 2)
  • have a score of ≥ 18 on the Hamilton Depression Rating Score 17-item (HDRS-17)
  • have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening able to adhere to the treatment schedule
  • Pass the TMS adult safety screening (TASS) questionnaire
  • have normal thyroid functioning based on pre-study blood work
Read More
Exclusion Criteria
  • have a history of substance dependence or abuse within the last 3 months
  • have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump
  • have active suicidal intent
  • are pregnant
  • have a lifetime MINI diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic symptoms
  • have a MINI diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia assessed by a study investigator to be primary and causing greater impairment than MDD
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
iTBSiTBSintermittent Theta Burst Stimulation (iTBS) five days per week for 4-6 weeks
10Hz10HzHigh Frequency Left repetitive transcranial magnetic stimulation five days per week for 4-6 weeks
Primary Outcome Measures
NameTimeMethod
Change in the Hamilton Depression Rating scale 17-item (HDRS-17) scorebaseline, 1, 4, and 12 weeks post-treatment

A 50% improvement in the score is considered response to rTMS. A final score of \<8 is categorized as remission.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Non-Invasive Neurostimulation Therapies lab, University of British Columbia

🇨🇦

Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath